- PharmaCielo is the first and only Colombian cannabis company to receive the internationally recognized ISO 9001:2015 certification
- ISO 9001 certification affirms the company's commitment to producing the highest quality medicinal-grade cannabis oils and derived products
TORONTO and RIONEGRO, Colombia, March 19, 2019 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV:PCLO), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is pleased to announce the Company has received the ISO 9001:2015 certification for its cultivation and extraction operations.
The ISO 9001 certification, awarded to PharmaCielo, covers the production of vegetable materials for the propagation, flowering and production of both psychoactive (THC) and non-psychoactive (CBD) cannabis. It was achieved following a rigorous audit process conducted at the Company's Colombian facilities by inspection and certification company SGS.
"PharmaCielo and our people continue to be the trailblazers of the Colombian cannabis industry, and we keep raising the bar. We were Colombia's first licensed producer, and first recipient of quota for propagation, among other milestones of industry leadership. Now, we are the first and only local cannabis producer to receive this coveted quality assurance certification," said David Attard, CEO at PharmaCielo. "Receiving and adhering to the high quality requirements of the ISO 9001 standard truly sets PharmaCielo apart and further attests to our commitment to production of the highest quality medicinal cannabis oils."
"The recognition provided is the result of the quality and high operating standards our Colombian team brings to the nursery," said Federico Cock-Correa, president of PharmaCielo Colombia Holdings SAS. "Without the dedication of our team, recognition of the quality and consistency of our operations would not be possible."
ISO 9001 is the international standard that specifies requirements for a quality management system (QMS). Organizations use the standard to demonstrate their ability to consistently provide products and services that meet customer and regulatory requirements.
"As the global medicinal cannabis market continues to evolve, and additional markets open for the use of medical cannabis and derived products, companies that can assure customers, patients, healthcare providers and regulators of the quality and consistency of the product will rise to the top. As such, PharmaCielo is well positioned to become the preferred global supplier of medicinal-grade cannabis oil extracts," added Dr. Delon Human, PharmaCielo’s Global Head, Health and Innovation.
The ISO 9001:2015 certification is another layer in PharmaCielo's commitment to high quality and high operational standards. PharmaCielo's processing facilities have been designed and operate to fulfill GMP (Good Manufacturing Processes) standards, ensuring that products are consistently high in quality and guarantee total traceability. Receipt of GMP certification for the Research and Technology Centre (RTC), as the centre of medicinal oil extraction processes, is expected in coming months.
PharmaCielo Ltd. (TSXV:PCLO) is a global company, headquartered in Canada, with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered at its nursery and propagation centre located in Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo and PharmaCielo Colombia Holdings are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that Colombia's ideal location will play in building a sustainable business in the medical cannabis industry, and the Company, together with its directors and executives, is executing on a business plan focused on supplying the international marketplace.
For further information:
About the International Organization for Standardization (ISO)
ISO is an independent, non-governmental international organization with a membership of 164. Through its members, it brings together experts to share knowledge and develop voluntary, consensus-based, market relevant International Standards that support innovation and provide solutions to global challenges, with 786 technical committees and subcommittees to take care of standards development, and more than 135 employees at ISO's Central Secretariat in Geneva, Switzerland.
SGS is the world's leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 97,000 employees, SGS operates a network of over 2,600 offices and laboratories around the world.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
This press release contains forward-looking statements. Forward-looking statements can be identified by the use of words such as, "expects", "is expected", "intends", "believes", or variations of such words and phrases or state that certain actions, events or results "may" or "will" be taken, occur or be achieved. Forward-looking statements are based on assumptions, including with respect to PharmaCielo's planned products, and the ability to execute its business plan that management believes are reasonable in the circumstances, but the actual results, performance or achievements of PharmaCielo's business may be materially different from any future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements can be affected by known and unknown risks, uncertainties and other factors, including, but not limited to, the equity markets generally, risks associated with early stage companies, risks associated with the regulation of cannabis and cannabinoid derivatives, failure to obtain necessary TSXV approval, competition for PharmaCielo's planned products, risks associated with operating in Colombia, and currency exchange risk. Accordingly, readers should not place undue reliance on forward-looking statements.
Except as required by law, PharmaCielo undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information: Media Relations: International: Gal Wilder, Cohn & Wolfe, +1.647.259.3261, [email protected]; Colombia: María Paula Peña Fdz., SPR GROUP S.A., PBX: 57-1 2877234, [email protected]; Investor Inquiries: [email protected]